Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...
Bayer plans to wield Recursion’s drug discovery platform—combining artificial intelligence with automated, “wet lab” biology experiments—to comb through its libraries of potential small molecule ...
Recursion Pharmaceuticals Inc., a biotech company leveraging artificial intelligence to discover new therapies, has raised a $60 million series B financing led by the Silicon Valley-based venture firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results